Protagonist Therapeutics Inc (PTGX) Return on Assets ROA from the third quarter of 2026 to third quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Sep 30 2026 to Sep 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Protagonist Therapeutics inc   (NASDAQ: PTGX)


Protagonist Therapeutics Inc 's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Protagonist Therapeutics Inc 's ROA in the third quarter of 2026?
Protagonist Therapeutics inc achieved a return on average assets (ROA) of 39.98 % in its third quarter of 2026, this is above PTGX's average return on assets of -25.53%.
Protagonist Therapeutics Inc assets over the 12 months ending in its third quarter of 2026 are valued at $852 million

ROA has improved compared to 11% in the second quarter of 2026, due to net income growth.

However, within the Healthcare sector 89 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2026 quarter, so far to 3403, from total ROA ranking in the second quarter of 2026 at 4043.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Total Assets Change 64.32 % 27.12 % -6.24 % -10.32 % 16.11 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million 341 81 -116 -132 46
Return On Assets (TTM) 39.98 % 11 % -16.81 % -18.72 % 6.35 %
PTGX's Total Ranking # 3403 # 4043 # 987 # 854 # 767
Total Assets (TTM) in million 1,154 889 697 668 702
Seq. Total Assets Change 29.79 % 27.46 % 4.38 % -4.85 % 0.42 %
Seq. Net Income Change 35.1 % 4204.76 % - - -

PTGX's 5 Years Annual ROA >> Back to PTGX Management Effectiveness >> Compare PTGX ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 36
Sector # 90
Overall # 551

Return On Assets Statistics
High Average Low
42.46 %
-25.53 %
-63.84 %
(Dec 31 2024)   (Dec 31 2016)





Financial Statements
Protagonist Therapeutics Inc 's Assets $ 1,154 million PTGX's Balance sheet
Protagonist Therapeutics Inc 's Income $ 220 million Quarterly PTGX's Income Statement
PTGX's Income by Division See PTGX's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change 0.23 % 108.26 % 44.47 % -28.78 % 7.16 %
Total Assets in million 747 745 358 248 348
Y / Y Net Income Change - - - - -
Net Income in million -130 275 -79 -127 -126
Annual Return On Assets -17.43 % 36.93 % -22.07 % -51.44 % -36.11 %

PTGX's 5 Years Annual ROA >> Back to PTGX Management Effectiveness >> Compare PTGX ROA to its Competitors



More Return On Assets Ratios
PTGX's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
PTGX's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for PTGX's Competitors
Subscribers only: Roa for Protagonist Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for PTGX's Customers

You may also want to know
PTGX's Roi PTGX's Inventory Turnover Ratio PTGX's Growth Rates PTGX's Dividend Comparisons
PTGX's Profitability Ratios PTGX's Asset Turnover Ratio PTGX's Dividend Growth
PTGX's Roe PTGX's Valuation Ratios PTGX's Financial Strength Ratios PTGX's Dividend Payout Ratio



Companies with similar Return On Assets at Sep 30 2026, within Healthcare Sector ROA
Exelixis Inc   63.88 %
Rigel Pharmaceuticals Inc  59.56 %
Alnylam Pharmaceuticals Inc   46.08 %
Ironwood Pharmaceuticals inc   42.53 %
Aurinia Pharmaceuticals Inc   40.63 %
Nurix Therapeutics Inc   38.61 %
Indivior Pharmaceuticals Inc   36.35 %
Rallybio Corporation  34.55 %
Idexx Laboratories Inc  34.05 %
Zevra Therapeutics Inc   26.33 %
Caredx Inc   25.74 %
Medpace Holdings Inc   24.47 %
Acadia Pharmaceuticals Inc   21.60 %
Standard Biotools Inc   21.56 %
Eli Lilly And Company  21.24 %
Iradimed Corporation  20.89 %
Resmed Inc   18.67 %
Alector Inc   18.37 %
Corcept Therapeutics Inc  18.09 %
Chemed Corporation  17.73 %
Halozyme Therapeutics Inc   17.26 %
Pro dex Inc   16.75 %
Denali Therapeutics Inc   16.42 %
Krystal Biotech Inc   15.48 %
West Pharmaceutical Services Inc   15.47 %
Dexcom Inc   15.47 %
Intuitive Surgical Inc   14.71 %
Vertex Pharmaceuticals Inc  14.16 %
Neurocrine Biosciences Inc   13.69 %
Illumina Inc   13.43 %

Date modified: 2026-11-08T13:41:06+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.